SynthesisNature communications2017
Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility.
Erratum issuedOpen access · goldAbstract readMeta-Analysis
In one paragraph
Synthesis in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 4 pooled it
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 4 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Cross-cancer pleiotropic analysis identifies three novel genetic risk loci for colorectal cancer.Human molecular genetics · 2023Pooled it
- Association of Single-Nucleotide Variants in the Human Leukocyte Antigen and Other Loci With Childhood Hodgkin Lymphoma.JAMA network open · 2022Pooled it
- Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.Nature communications · 2021Pooled it
- Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma.Blood · 2018Pooled it
- Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.Health technology assessment (Winchester, England) · 2020Trial
- Proteome-wide Mendelian randomization identifies protein associations and therapeutic targets for B-cell malignancy.Blood neoplasia · 2026Article
- Unfolding the enigma of familial Hodgkin lymphoma: Current insights.World journal of clinical cases · 2026Review
- Integration of transcriptome-wide association study and gene-based association analysis identifies candidate genes for Hodgkin lymphoma.Journal of cancer research and clinical oncology · 2025Article
- Mendelian randomization of immune cell phenotypes to discover potential drug targets for B-cell malignancy.Blood cancer journal · 2025Article
- Towards IVDR-compliance by implementing quality control steps in a quantitative extracellular vesicle-miRNA liquid biopsy assay for response monitoring in patients with classic Hodgkin lymphoma.Journal of extracellular biology · 2024Article
- Role of non-chromosomal birth defects on the risk of developing childhood Hodgkin lymphoma: A Children's Oncology Group study.Pediatric blood & cancer · 2024Article
- Design and quality control of large-scale two-sample Mendelian randomization studies.International journal of epidemiology · 2023Article
- Article
- Improve the model of disease subtype heterogeneity by leveraging external summary data.PLoS computational biology · 2023Article
- Identification and Interpretation of eQTL and eGenes for Hodgkin Lymphoma Susceptibility.Genes · 2023Article
- Discovery of novel predisposing coding and noncoding variants in familial Hodgkin lymphoma.Blood · 2023Article
- Learning from the nexus of autoimmunity and cancer.Immunity · 2023Review
- A Genome-Wide Association Study Identified Novel Genetic Susceptibility Loci for Oral Cancer in Taiwan.International journal of molecular sciences · 2023Article
- New molecular targets in Hodgkin and Reed-Sternberg cells.Frontiers in immunology · 2023Review
- NFkB Pathway and Hodgkin Lymphoma.Biomedicines · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
36 authors at 20 institutions in 18 countries.
Amit SudDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.ORCID http://orcid.org/0000-0002-6133-0164
Hauke ThomsenDivision of Molecular Genetic Epidemiology, German Cancer Research Centre, Heidelberg, 69120, Germany.ORCID http://orcid.org/0000-0001-5951-3116
Philip J LawDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.ORCID http://orcid.org/0000-0001-9663-4611
Asta FörstiDivision of Molecular Genetic Epidemiology, German Cancer Research Centre, Heidelberg, 69120, Germany.
Miguel Inacio da Silva FilhoDivision of Molecular Genetic Epidemiology, German Cancer Research Centre, Heidelberg, 69120, Germany.
Amy HolroydDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
Peter BroderickDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.ORCID http://orcid.org/0000-0002-8348-5829
Giulia OrlandoDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
Oleg LeniveDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
Lauren WrightDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
Rosie CookeDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
Douglas EastonCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, CB1 8RN, UK.
Paul PharoahCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, CB1 8RN, UK.ORCID http://orcid.org/0000-0001-8494-732X
Alison DunningCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, CB1 8RN, UK.
Julian PetoDepartment of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
Federico CanzianGenomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.
Rosalind EelesDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.ORCID http://orcid.org/0000-0002-3698-6241
ZSofia Kote-JaraiDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
Kenneth MuirInstitute of Population Health, University of Manchester, Manchester, M1 3BB, UK.ORCID http://orcid.org/0000-0001-6429-988X
Nora PashayanCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK.ORCID http://orcid.org/0000-0003-0843-2468
PRACTICAL consortium
Per HoffmannDepartment of Biomedicine, Division of Medical Genetics, University of Basel, Basel, 4031, Switzerland.
Markus M NöthenInstitute of Human Genetics, University of Bonn, Bonn, 53127, Germany.
Karl-Heinz JöckelUniversity of Duisburg-Essen, Essen, 47057, Germany.
Elke Pogge von StrandmannDepartment of Internal Medicine, University Hospital of Cologne, Cologne, 50937, Germany.
Tracy LightfootDepartment of Health Sciences, University of York, York, YO10 5DD, UK.
Eleanor KaneDepartment of Health Sciences, University of York, York, YO10 5DD, UK.
Eve RomanDepartment of Health Sciences, University of York, York, YO10 5DD, UK.
Annette LakeMRC University of Glasgow Centre for Virus Research, Glasgow, G61 1QH, UK.
Dorothy MontgomeryMRC University of Glasgow Centre for Virus Research, Glasgow, G61 1QH, UK.
Ruth F JarrettMRC University of Glasgow Centre for Virus Research, Glasgow, G61 1QH, UK.
Anthony J SwerdlowDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
Andreas EngertDepartment of Internal Medicine, University Hospital of Cologne, Cologne, 50937, Germany.
Nick OrrDivision of Molecular Pathology, The Institute of Cancer Research, London, SW7 3RP, UK.
Kari HemminkiDivision of Molecular Genetic Epidemiology, German Cancer Research Centre, Heidelberg, 69120, Germany.
Richard S HoulstonDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK. richard.houlston@icr.ac.uk.
Institute of Cancer Research · GBGerman Cancer Research Center · DEUniversity of Cambridge · GBNational Cancer Institute · USUniversity of Southern California · USKarolinska Institutet · SEMRC University of Glasgow Centre for Virus Research · GBUniversity of York · GBBrigham and Women's Hospital · USManchester Academic Health Science Centre · GBTranslational Research Institute · AUUniversity Hospital Cologne · DEUniversity of Bonn · DEUniversity of Washington · USAarhus University · DKAmerican Cancer Society · USCancer Prevention Institute of California · USCity of Hope · USErasmus MC · NLFred Hutch Cancer Center · US
Funding
Epidemiological and Clinical Translational Studies Post Genome-Wide AssociationU19CA148537 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI EASTON, DOUGLAS FREDERICK, EELES, ROSALIND · 2010 to 2014
$10.4MImputation-based approach to identify low frequency variants in prostate cancerU01CA188392 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SCHUMACHER, FREDRICK RAY · 2014 to 2016
$1.9MCancer Research UK 10119Cancer Research UK 10124Cancer Research UK 13065Cancer Research UK 14136Cancer Research UK 15007Cancer Research UK 16561Cancer Research UK 17528Cancer Research UK C1287/A10118Cancer Research UK C1287/A16563Cancer Research UK C1298/A8362Cancer Research UK C16913/A6135Cancer Research UK C490/A10124Cancer Research UK C5047/A10692Cancer Research UK C5047/A3354Cancer Research UK C5047/A7357Cancer Research UK C570/A16491Cancer Research UK C8221/A19170Medical Research Council G0000934Medical Research Council G0401527Medical Research Council G1000143Medical Research Council MC_UU_12014/3Medical Research Council MR/M012190/1Medical Research Council MR/N003284/1NCI NIH HHS U01 CA188392NCI NIH HHS U19 CA148537NHLBI NIH HHS HHSN268201200008CNHLBI NIH HHS HHSN268201200008IWellcome TrustWellcome Trust 068545/Z/02Wellcome Trust 076113Wellcome Trust 085475Wellcome Trust 090532/Z/09/Z
Abstract
Several susceptibility loci for classical Hodgkin lymphoma have been reported. However, much of the heritable risk is unknown. Here, we perform a meta-analysis of two existing genome-wide association studies, a new genome-wide association study, and replication totalling 5,314 cases and 16,749 controls. We identify risk loci for all classical Hodgkin lymphoma at 6q22.33 (rs9482849, P = 1.52 × 10
Indexed as
Genetic Predisposition to DiseaseAllelesGenome-Wide Association StudyHLA-DP beta-ChainsHLA-DRB1 ChainsHodgkin DiseaseHumansPolymorphism, Single NucleotideHLA-DPB1 antigenHLA-DP beta-ChainsHLA-DRB1 Chains
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.